课题基金 / 基金详情

Administrative Supplement to SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responses

Administrative Supplement to SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responses
SMART NANP 的行政补充:用于与人体免疫系统沟通和调节治疗反应的新分子平台
批准号:
10798083
负责人:
Kirill A Afonin
金额:
$11.82万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-02-01 至 2026-01-31

项目摘要

项目成果

Kirill A Afonin的其他基金

相似基金

相关文献

中文摘要
翻译
主要研究者/项目负责人(最后,第一,中间):Afonin,Kirill,A 项目摘要 如果医疗保健提供者配备了生物相容性,可生物降解,强大,负担得起的, 将联合收割机治疗方式与受控作用机制相结合的治疗选择?如果这 多功能技术具有学习能力,可以接受教育,以识别患者特有的疾病, 通过改变基本的细胞过程来干扰它们的进程?如果同样的公式 可以提供一种额外的手段来控制患者的免疫反应, 最小毒性的治疗效果?这些新一代的治疗方法将成为一种游戏 在帮助预防,检测,诊断和治疗疾病和残疾的源头改变。与 在MIRA(R35)资金的支持下,我们设想了一个数据驱动的平台,SMART NANP(特定的,模块化的, 可调节的、可再现的和靶向的核酸纳米颗粒),由自组装核酸编码。通过 核酸控制着遗传信息在所有生命形式中的流动, 获得有关主要细胞过程和疾病起源的新知识。除了它们多样的生物学特性 这些生物聚合物可以被编程为具有特定物理化学性质的NANP, 这些功能决定了NANP的生物学行为,具有无限的可能性, 行为通过分子信号。我们最近发现,不同的建筑参数和 递送至原代人免疫细胞的NANP组合物可以激活单核细胞和树突细胞, 产生I型和III型干扰素。这项关于NANP免疫识别的开创性工作强调了 该技术在疫苗和免疫治疗领域的不可预见的临床应用。限定的 任何给定NANP的结构-功能关系将允许其有条件的激活, 免疫识别或任何其它治疗活性。与此 概念,我们介绍了两个正交的概念,治疗性NANP可以有条件地激活, 人类癌细胞释放预先编程的治疗剂。通过将这些突破和其他 我的实验室的初步发现,在当前的应用程序中突出显示,并将它们集成到一个统一的 SMART NANP网络,可编程控制生物分布、免疫活性和治疗活性 模块,我们将推进目前针对传染病和癌症的治疗方法(通过 基于NANP的疫苗和免疫疗法)、心血管疾病(通过 凝血酶靶向NANP),并解决药物过量和安全性问题(通过可生物降解的性质, NANP及其受控失活)。为了最大限度地成功翻译这项技术, 拟议的计划将采用跨核酸纳米技术领域的多学科方法, 免疫学、药物递送、转化肿瘤学和机器学习。该计划的长期目标是 将SMART NANP提升到临床应用水平。
英文摘要
Principal Investigator/Program Director (Last, First, Middle): Afonin, Kirill, A PROJECT SUMMARY What if healthcare providers were equipped with biocompatible, biodegradable, robust, and affordable treatment options that combine therapeutic modalities with controlled mechanisms of action? What if this versatile technology had learning capacity and could be educated to recognize patient-specific diseases and interfere with their progression by redirecting fundamental cellular processes? What if the very same formulation could offer an additional means of control over patients’ immune responses and further advance favorable therapeutic outcomes with minimal toxicities? These next generation therapies would then become a game changer in helping to prevent, detect, diagnose, and treat diseases and disabilities at their source. With the support from MIRA (R35) funding, we envision a data-driven platform, SMART NANPs (specific, modular, adjustable, reproducible, and targeted nucleic acid nanoparticles), encoded by self-assembling nucleic acids. By controlling the flow of genetic information across all forms of life, nucleic acids have become instrumental in acquiring new knowledge about major cellular processes and origins of diseases. Besides their diverse biological roles, these biopolymers can be programmed into NANPs with specified physicochemical properties and functionalities that dictate NANPs’ biological actions with endless possibilities for reprogramming cellular behavior through molecular signaling. We recently discovered that different architectural parameters and compositions of NANPs, delivered to primary human immune cells, can activate monocytes and dendritic cells to produce type I and type III interferons. This pioneering work on NANPs’ immunorecognition highlighted an unforeseen clinical application for this technology in the field of vaccines and immunotherapy. A defined structure-function relationship for any given NANP would then allow conditional actuation of its immunorecognition or any other therapeutic activity through a set of embedded architectural codes. With this notion, we introduced two orthogonal concepts of therapeutic NANPs which can be conditionally activated in human cancer cells to release pre-programmed therapeutics. By uniting these breakthroughs and other preliminary findings from my lab, as highlighted in the current application, and integrating them into a unified network of SMART NANPs with programmable control of biodistribution, immunological activity, and therapeutic modules, we will advance the current repertoire of therapies against infectious diseases and cancers (through NANP-based vaccines and immunotherapies), cardiovascular diseases (through regulated coagulation by thrombin-targeting NANPs), and address drug overdose and safety issues (through the biodegradable nature of NANPs and their controlled deactivation). To maximize the successful translation of this technology, the proposed program will employ a multidisciplinary approach that spans the fields of nucleic acid nanotechnology, immunology, drug delivery, translational oncology, and machine learning. The long-term goal of this program is to elevate SMART NANPs to the level of clinical use.
期刊论文(31)
专著(0)
科研奖励(0)
会议论文
Aptamer Conjugated RNA/DNA Hybrid Nanostructures Designed for Efficient Regulation of Blood Coagulation.
适体缀合 RNA/DNA 混合纳米结构,专为有效调节凝血而设计。
DOI: 10.1007/978-1-0716-3417-2_19
发表时间: 2023
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Rolband,LewisA, Ke,Weina, Afonin,KirillA]
通讯作者: Afonin,KirillA
Characterization of RNA Nanoparticles and Their Dynamic Properties Using Atomic Force Microscopy.
使用原子力显微镜表征 RNA 纳米颗粒及其动态特性。
DOI: 10.1007/978-1-0716-3417-2_12
发表时间: 2023
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Lushnikov,AlexanderJ, Avila,YelixzaI, Afonin,KirillA, Krasnoslobodtsev,AlexeyV]
通讯作者: Krasnoslobodtsev,AlexeyV
Assessment of Intracellular Compartmentalization of RNA Nanostructures.
RNA 纳米结构细胞内区室化的评估。
DOI: 10.1007/978-1-0716-3417-2_14
发表时间: 2023
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Radwan,Yasmine, Afonin,KirillA, Johnson,MBrittany]
通讯作者: Johnson,MBrittany
Dynamic Nanostructures for Conditional Activation and Deactivation of Biological Pathways.
用于生物途径的条件激活和失活的动态纳米结构。
DOI: 10.1007/978-1-0716-3417-2_22
发表时间: 2023
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Radwan,Yasmine, Rebolledo,LauraP, Panigaj,Martin, Afonin,KirillA]
通讯作者: Afonin,KirillA
共 22 条
    Multiplexed electronic counting of scarce protein targets using nucleic acid nanoparticles
    Multiplexed electronic counting of scarce protein targets using nucleic acid nanoparticles
    SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responses
    SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responses
    海外基金